BLSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
BlossomHill Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 18, 2026
$14.16+0.22 (+1.58%)
Close on Oct 19, 2026
- Market cap
- $38.43M
- P/E (TTM)
- –
- Dividend yield
- –
SEC filings
4 of BlossomHill Therapeutics's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Quarterly report | 10-Q | Jun 30, 2026 | Sep 18, 2026 | SEC EDGAR |
| Current report | 8-K | Sep 18, 2026 | Sep 18, 2026 | SEC EDGAR |
| Current report | 8-K | Sep 15, 2026 | Sep 15, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 10, 2026 | Aug 10, 2026 | SEC EDGAR |